KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: A FIL study

S. Ferrero, D. Rossi, A. Rinaldi, A. Bruscaggin, V. Spina, C.W. Eskelund, A. Evangelista, R. Moia, I. Kwee, C. Dahl, A. Di Rocco, V. Stefoni, F. Diop, C. Favini, P. Ghione, A.M. Mahmoud, M. Schipani, A. Kolstad, D. Barbero, D. NoveroM. Paulli, A. Zamò, M. Jerkeman, M.G. Da Silva, A. Santoro, A. Molinari, A. Ferreri, K. Grønbæk, A. Piccin, S. Cortelazzo, F. Bertoni, M. Ladetto, G. Gaidano

Research output: Contribution to journalArticle

Cite this

Ferrero, S., Rossi, D., Rinaldi, A., Bruscaggin, A., Spina, V., Eskelund, C. W., Evangelista, A., Moia, R., Kwee, I., Dahl, C., Di Rocco, A., Stefoni, V., Diop, F., Favini, C., Ghione, P., Mahmoud, A. M., Schipani, M., Kolstad, A., Barbero, D., ... Gaidano, G. (2020). KMT2D mutations and TP53 disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: A FIL study. Haematologica, 105(6), 1604-1612. https://doi.org/10.3324/haematol.2018.214056